In summary, in the subcutaneous setting, combined RASG12C(ON) and SHP2 inhibition renders immune-excluded NSCLC tumours responsive to anti-PD-1 immunotherapy, with further addition of anti-CTLA-4 causing eradication of most tumours. The gene discussed is CTLA4; the disease is neoplasm.